Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Philippe Moreau,Luděk Pour,Anna Sureda Balari,Lauriane Clement-Filliatre,Cyrille Hulin,Helen Mccarthy,Kenshi Suzuki,Maria Delioukina,Hila Magen,Michele Kosh,Albert Oriol,Shiyi Yang,Christoph Heuck,Mathias Haenel,Shinsuke Iida,Lionel Karlin,Hartmut Goldschmidt,Cyrille Touzeau,Ajai Chari,Vladimír Maisnar ,Vânia Hungria ,Paula Rodríguez‐Otero

doi:10.1182/blood-2020-134935

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Philippe Moreau, Luděk Pour + Show 20 more

Open Access

https://doi.org/10.1182/blood-2020-134935

Copy DOI

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Full Text